stoxline Quote Chart Rank Option Currency Glossary
DexCom, Inc. (DXCM)
133.86  -2.66 (-1.95%)    04-17 16:00
Open: 136.07
High: 136.64
Volume: 3,213,529
Pre. Close: 136.52
Low: 132.875
Market Cap: 51,605(M)
Technical analysis
2024-04-17 4:46:14 PM
Short term     
Mid term     
Targets 6-month :  159.88 1-year :  165.85
Resists First :  136.88 Second :  142
Pivot price 137.66
Supports First :  128.61 Second :  107.01
MAs MA(5) :  136.13 MA(20) :  137.2
MA(100) :  125.5 MA(250) :  116.39
MACD MACD :  1.7 Signal :  2.6
%K %D K(14,3) :  31.5 D(3) :  40.4
RSI RSI(14): 48.1
52-week High :  142 Low :  74.75
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ DXCM ] has closed above bottom band by 8.3%. Bollinger Bands are 38.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 137.03 - 137.79 137.79 - 138.4
Low: 130.53 - 131.6 131.6 - 132.48
Close: 132.28 - 133.87 133.87 - 135.17
Company Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Headline News

Tue, 16 Apr 2024
EVP Strategy and Corporate Dev Matthew Dolan Sells Shares of DexCom Inc (DXCM) - Yahoo Finance

Mon, 15 Apr 2024
DexCom (DXCM) Stock Moves -1.16%: What You Should Know - Yahoo Canada Finance

Mon, 15 Apr 2024
DexCom Inc. stock underperforms Monday when compared to competitors - MarketWatch

Mon, 15 Apr 2024
DexCom (DXCM), MD Revolution Unite to Boost Diabetes Management - Yahoo Finance

Mon, 15 Apr 2024
Stratos Wealth Partners LTD. Sells 286 Shares of DexCom, Inc. (NASDAQ:DXCM) - Defense World

Sun, 14 Apr 2024
DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Financial Counselors Inc. - Defense World

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Medical - Devices
Shares Out 386 (M)
Shares Float 380 (M)
Held by Insiders 0.4 (%)
Held by Institutions 103 (%)
Shares Short 14,570 (K)
Shares Short P.Month 16,650 (K)
Stock Financials
EPS 1.28
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.36
Profit Margin 14.9 %
Operating Margin 20.9 %
Return on Assets (ttm) 6.4 %
Return on Equity (ttm) 25.7 %
Qtrly Rev. Growth 26.8 %
Gross Profit (p.s.) 0
Sales Per Share 9.38
EBITDA (p.s.) 2.03
Qtrly Earnings Growth 181 %
Operating Cash Flow 749 (M)
Levered Free Cash Flow 477 (M)
Stock Valuations
PE Ratio 103.76
PEG Ratio 2.3
Price to Book value 24.92
Price to Sales 14.25
Price to Cash Flow 68.94
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android